期刊文献+

顺铂序贯恩度与单纯顺铂胸腔内灌注治疗恶性胸腔积液的临床对照研究 被引量:29

A Comparision Between Intrapleural Injection of Cisplatin Combined with Endostar and Cisplatin Alone in the Treatment for Malignant Pleural Effusion
原文传递
导出
摘要 [目的]观察胸腔内灌注顺铂序贯恩度与单纯顺铂治疗恶性胸腔积液的疗效及安全性。[方法]120例患者随机分为单纯顺铂胸腔灌注组(对照组)和顺铂序贯恩度胸腔灌注组(试验组)。治疗前均先排尽胸水,对照组单纯注入顺铂30~40mg,d1~3,治疗组在对照组基础上于第4d胸腔内滴注恩度90mg。比较两组疗效和不良反应。[结果]试验组患者CR14例,PR29例,SD12例,PD5例,总有效率为71.67%;对照组患者CR10例,PR21例,SD20例,PD9例,总有效率为51.67%;两组总有效率差异具有统计学意义(χ2=5.08,P=0.02)。分层分析发现,恩度对大于1000ml胸水患者效果较好,两组疗效差异有统计学意义。[结论]胸腔内灌注顺铂序贯恩度疗效优于单纯顺铂,特别对于胸水较多的患者,效果会更好,不增加化疗的不良反应,值得临床推广。 [Purpose] To investigate the efficacy and safety of intrapleural injection of cisplatin combined with endostar and cisplatin alone in the treatment for malignant pleural effusion.[Methods] One hundred and twenty patients were randomly divided into experimental group and control group.Before treatment the pleural effusions were drained.The experimental group was given cisplatin 30~40mg,d1~3 and endostar 90mg,d4.The control group was given the same treatment except for endostar.[Results] Among the 60 patients in the experimental group,14 cases were complete response(CR),29 cases were partial response(PR),12 cases were stable disease(SD),5 cases were progression of disease(PD),the overall response rate was 71.67%;among the 60 patients in the control group,10 cases were CR,21 cases were PR,20 cases were SD,9 cases were PD,and the overall response rate was 51.67%.There was significant diffe-rence between the two groups(χ2=5.08,P=0.02).Stratified analysis showed that endostar(combined with cisplatin) had a significant efficacy to patients with hydrothorax over 1000ml.[Conclusion] The response on intrapleural injection of endostar combined with cisplatin is superior to that cisplatin alone in the treatment for malignant pleural effusion,especially for heavy hydrothorax and it does not increase chemotherapeutic toxicity.
机构地区 衢州市人民医院
出处 《肿瘤学杂志》 CAS 2013年第5期386-389,共4页 Journal of Chinese Oncology
基金 衢州市科技局(2011083)
关键词 恩度 顺铂 恶性胸腔积液 endostar cisplatin pleural effusion malignant
  • 相关文献

参考文献14

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 2Ner-agi Miandoafi S.Malignant" pleural effusion ,current and evolvimg approaches for its diagnosis and management[J]. Lung cancer, 2006,54(1): 1-9. 被引量:1
  • 3Folkman J.Role of angiogenesis in tumor growth and metastasis[J].Semin Oncol,2002,29(6 Suppl 16):15-18. 被引量:1
  • 4Winkler F,Kozin SV,Tong RT,et al.Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor respcrse to radiation:role of oxygenation,angiopoietin-1, and matrix metallo proteinases[J].Cancer Ce11,2004,6(6): 553-563. 被引量:1
  • 5Tamsma JT, Keizer H J, Meiners AE.Pathogenesis of malig- nant ascites: Starling's law of capillary hemodynamics re- visited[J].Ann Oncol, 2001,12(10): 1353-1357. 被引量:1
  • 6Tong RT,Boucher Y,Kozin SV,et al.Vaseular normaliza- tion by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vascula- ture and improves drug penetration in tumors [J].Cancer Res, 2004,64(11):3731-3736. 被引量:1
  • 7Grove CS,Lee YC.Vascular endothelial growth factor:the key mediator in pleural effusion formation [J].Curropin Pulm Med,2002,8(4):294-301. 被引量:1
  • 8Fang F,Chen P,Wu X,et al.Therapeutic effects of recom- binant human endostatin adenoviros in a mouse model of malignant pleural effusion[J]. J Cancer Res Clin Oncol, 2009, 135(9):1149-1157. 被引量:1
  • 9Shichiri M,Hirata Y. Antiangiogenesis signals by endo- statin[J]. FASEB J ,2001,15(6):1044-1053. 被引量:1
  • 10Jain RK,Duda DG,Clark JW,et al.Lessons from phase Ill clinical trials on anti-VEGF therapy for cancer[J].Nat Clin Pract Oncol, 2006,3(1):24-40. 被引量:1

二级参考文献54

共引文献664

同被引文献308

引证文献29

二级引证文献149

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部